The Hero study gives Myovant an opportunity to change the way hormone-sensitive prostate cancer is treated.
Iterum should soon find out if it has an approvable asset in the antibiotic sulopenem, but even if the group succeeds it still has a hard road ahead.
Daiichi Sankyo’s incredible stock market performance stands out amid the usual mixed bag of fallers and risers among biopharma’s mid- and small caps.
The Japanese company is to hand across $3bn to Roivant for various subsidiaries that hold an eclectic portfolio of assets.
Nucana’s recent setback with Acelarin adds to the long list of pancreatic cancer failures, and a look at the late-stage pipeline shows little concrete progress.
The company has quietly emerged as the key player to watch in an area that has seen several setbacks of late.
The usual story of positive data and clinical failure influencing company stock performance was given added interest in the second quarter with price fixing allegations…
Yet another project brought in through business development fails, exposing Sumitomo’s limited pipeline.
Payment of an overdue $120m Astrazeneca milestone, plus two other obligations, has been met through a loan facility with undisclosed terms.